ClinicalTrials.gg
RecruitingNCT06474273TACKLE-ITUpdated Aug 31, 2026

A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients

A Phase 3 interventional study of Methylprednisolone and Prednisone in Rejection; Transplant, Kidney and Rejection; Transplant, Pancreas, sponsored by University of Sydney. Recruiting at 30 sites in 3 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by University of Sydney · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Study summary

After a kidney or a kidney-pancreas transplant, some patients may face problems with their new organs. This happens because the body sometimes makes a mistake and tries to get rid of the organ. This problem is called rejection. One type of rejection is known as Acute T cell mediated rejection (TCMR). This can lead to many problems or even stop the transplant from working.

Doctors give strong steroids to treat this problem, but there are no rules for how much steroid to give. Too much steroids can cause problems like heart and bone problems, bad infections, and weight gain. That is why we need to find the right dose of steroids for each person to treat this.

TACKLE-IT is a study that will try to find the right steroid dose for treating rejection.

Read the detailed description

TACKLE-IT is an international, multi-centre, 2x2 factorial, PROBE-style, registry-embedded randomised controlled trial (RCT) that compares the effectiveness and safety of high vs low dose IV MP, and high vs low dose oral prednisone taper as the first-line therapy for acute TCMR in kidney and SPK transplant recipients. This RCT was conceived and developed through extensive consultation and collaboration with our key stakeholders, including transplant recipients with lived experience and the International TCMR Working Group with sponsorship by 4 international transplant societies (The Transplantation Society (TTS), American Society of Transplantation (AST), European Society of Transplantation (ESOT) and Transplant Society of Australia and New Zealand (TSANZ). TACKLE-IT is led by an international multi-disciplinary team of transplant health professionals, clinical trialists, biostatisticians, health economist, social scientist, consumers.

TACKLE-IT will address the critical unmet need and resolve a decades-long unanswered question, 'What is the minimally acceptable, safe and effective steroid dose for the treatment of acute TCMR in kidney and SPK transplant recipients?'

02

Conditions studied

  • Rejection; Transplant, Kidney
  • Rejection; Transplant, Pancreas

Keywords

  • Acute T cell mediated rejection
03

In context

Lead sponsor

University of Sydney is the lead sponsor of 94 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants or their legal guardian must be able to understand and provide written ;
  • Stated willingness to comply with all study procedures and availability for the duration of the study;
  • All ethnic and gender groups will have equal access to the study;
  • All children (aged 2+ years) and adults who have received a kidney or SPK transplant with proven *acute TCMR (≥ Banff borderline (minimum i1 score) whether clinical or subclinical).

    • Individuals with the following are eligible for inclusion:

      i. Concurrent acute TCMR and microvascular inflammation (MVI) defined as g+ptc, but without ABMR diagnosis.

ii. Concurrent acute TCMR and chronic active TCMR.

Exclusion criteria

Exclusion Criteria:

Individuals meeting any of the following criteria will be excluded from participation:

  • Mixed rejection.
  • Active or chronic active ABMR.
  • Chronic active TCMR.
  • Isolated v1 without inflammation.
  • Concurrent renal disease, such as recurrent glomerulonephritis or polyomavirus nephropathy.
  • Active or active infection that preclude augmentation.
  • Use of other immunomodulatory agents, including, but not limited to, Rituximab, Anti-TNF monoclonal antibody, Belatacept, Abatacept, Janus kinase inhibitors, Eculizumab, Pegcetacoplan.
  • Enrolment in other interventional drug trials.
  • Use of other agents.
  • Unable to adhere to the study protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    Lower dose IV methylprednisolone x Lower dose oral prednisone

    Lower dose IV MP (250 mg daily x 3 days in adults or 150 mg/m² daily x 3, or to a max 250 mg/dose in children (\<18 years), with lower dose (25mg daily x 7 days, or 15mg/m² x 7 days, or to a max 25mg/dose for those \< 18 years ) oral prednisone augmentation then return to standard prednisone.

    Drug: Methylprednisolone · Drug: Prednisone

  • Experimental
    Lower dose IV methylprednisolone x Higher dose oral prednisone

    Lower dose IV MP (250 mg daily x 3 in adults or 150 mg/m² daily x 3, or to a max 250 mg/dose in children (\<18 years), with higher dose (50mg daily x 7, or 30mg/m² daily x 7, or to a max 50mg/dose for those \< 18 years) oral prednisone augmentation then return to standard prednisone.

    Drug: Methylprednisolone · Drug: Prednisone

  • Active comparator
    Higher dose IV methylprednisolone x lower dose oral prednisone

    Higher dose IV MP (500mg daily x 3 in adults or 300 mg/m² daily x 3 or to a max 500 mg/dose in children (\<18 years), with lower dose (25mg daily x 7 days, or 15mg/m² daily x 7 days, or to a max 25mg/dose for those \< 18 years) oral prednisone augmentation then return to standard prednisone.

    Drug: Methylprednisolone · Drug: Prednisone

  • Active comparator
    Higher dose IV methylprednisolone x higher dose oral prednisone

    Higher dose IV MP (500 mg daily x 3 in adults or 300 mg/m² daily x 3 or to a max 500 mg/dose in children (\<18 years), with higher dose (50mg daily x 7 days, or 30mg/m² daily x 7 days, or to a max 50mg/dose for those \< 18 years) oral prednisone augmentation, then return to standard prednisone.

    Drug: Methylprednisolone · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Histological resolution of biopsy-proven acute rejection

    Histological resolution of biopsy-proven acute rejection is defined by the absence of any biopsy proven acute rejection (BPAR) on follow-up biopsy, including Banff Borderline (i1 t1), mixed rejection, ABMR and chronic active TCMR using Banff 2022 criteria.

    Time frame: 12 weeks post-randomization

  2. Improvement in allograft function for clinical rejection; and defined by an average of at least 2 serum creatinine at baseline and at least 2 serum creatinine from 11-13 weeks

    Reduction in serum creatinine ≥20% is defined as the relative reduction in serum creatinine from baseline and at 11-13 weeks after randomisation, in the absence of dialysis or achieving freedom from dialysis. Staff are required to record the serum creatinine at each visit; or dates and modality of dialysis initiation and / or discontinuation.

    Time frame: 11 to 13 weeks post-randomization

  3. Avoidance of rescue therapies within 12 weeks post-randomization to achieve histological resolution and/or improvement in allograft function

    Use of rescue therapy is defined as: the use of any adjunctive T and B cell depleting therapies such as intravenous thymoglobulin, alemtuzumab, bortezomib, or rituximab, or additional doses of IV MP within the first 12 weeks after randomisation.

    Time frame: 12 weeks post-randomization

Secondary outcomes

  1. All cause death and death-censored graft loss

    All cause death and death-censored graft loss have been identified as the core outcomes for kidney transplant recipients. However, death and death-censored graft loss are anticipated to have a very low incidence at the 12 weeks post-randomization primary outcome ascertainment and were therefore not included in the primary composite outcome. They will be reported as principal secondary endpoints. All-cause death also includes cause-specific death (infections, cancers, cardiovascular-related, and other causes of death) at 12 weeks after randomisation.

    Time frame: At 12 weeks post-randomization

  2. Estimated glomerular filtration rate (eGFR)

    * Absolute eGFR (2021 CKD-EPI eGFR without race modifier for adults, and the CKiD U25 equation to estimate GFR in children \<18 years) 12, 24 and 48 weeks. * Decline in eGFR (slope) from randomization to 48 weeks.

    Time frame: At 12, 24 and 48 weeks post-randomization

  3. Urine albumin: creatinine ratios

    Urine ACR is measured as standard of care. Rationale: ACR screens for graft dysfunction and is a marker for graft outcomes

    Time frame: At 12, 24 and 48 weeks post-randomization

  4. Trajectories of serum creatinine changes

    Time frame: From randomization to 48 weeks post-randomization

  5. Development of acute antibody mediated rejection (ABMR) and mixed rejection (concomitant ABMR + TCMR)

    Development of acute antibody mediated rejection (ABMR) and mixed rejection (concomitant ABMR + TCMR) within 48 weeks after randomisation. ABMR and mixed rejection are defined according to the Banff 2022 criteria

    Time frame: 48 weeks post-randomization

  6. Development of chronic fibrosis in the allograft

    Development of chronic fibrosis in the allograft. This is defined as the absolute (Banff ci+ctscores) at 12 weeks

    Time frame: Baseline to 12 weeks post-randomization

  7. Infections (all types and sites)

    All types and number of events related to infections that required antimicrobials and hospitalisation for infections will be recorded.

    Time frame: Anytime from randomization to 48 weeks post-randomization

  8. Quality of life (QoL)

    QoL will be assessed using the EuroQol-5 Dimension-5 Level (EQ-5D-5L) for adult participants (aged ≥18 years). For paediatric participants (aged 2-17 years), age-appropriate versions of the EuroQol Youth version (EQ-5D-Y) will be used as follows: * Ages 2-7: EQ-5D-Y proxy version * Ages 8-17: EQ-5D-Y self-report version Both the EQ-5D-5L and EQ-5D-Y report utility scores ranging from -0.281 to 1 (EQ-5D-5L UK value set) and -0.109 to 1 (EQ-5D-Y, proxy or self-report), where 1 represents perfect health, 0 represents a health state equivalent to death, and negative scores represent health states worse than death. Higher scores indicate better health-related quality of life.

    Time frame: Baseline (at randomization), 12 weeks , 24 weeks , and 48 weeks post-randomization

  9. Cancer

    All types and sites

    Time frame: Anytime from randomization to 48 weeks

Other outcomes

  1. Steroid-related adverse effects

    Adaption from the Steroid Patient Reported Outcome (Steroid PRO).

    Time frame: 3 days post randomisation, 7 days post randomisation, week 12 post-randomisation, week 24 post-randomisation and week 48 post-randomisation

  2. Integrative Box Risk Prediction Score (iBOX)

    Graft survival prediction will be assessed using the Integrative Box Risk Prediction Score (iBOX), a validated composite risk prediction tool for kidney transplant outcomes. The iBOX score integrates clinical, functional, and immunological parameters including serum creatinine, proteinuria, biopsy findings, and presence of donor-specific antibodies to estimate the risk of allograft failure. The iBox score essentially assigns a numerical value based on these parameters, indicating the risk of allograft loss (kidney transplant failure).

    Time frame: Week 13 to week 48 post-randomisation

  3. Economic evaluation: Incremental costs and benefits

    Incremental costs and benefits (life years and quality adjusted life years gained) between the two treatment arms.

    Time frame: During the 52-week follow up period

  4. Process evaluation: patients' and clinicians' perspectives on the treatment of acute TCMR

    Semi-structured interviews will be conducted to elicit patients' perspectives and experiences of having acute TCMR, the adverse effects of the treatments. Health professionals' will also be interviewed to elicit their perspectives and experiences regarding the barriers, challenges, and enablers for implementing the intervention, the perceived benefits, and harms of the intervention and how the intervention should be delivered such that maximal interactions of the intervention are reached for the intended participants.

    Time frame: Anytime between week 12 and 48 of the trial

  5. Transplant biobank - analysis of TCMR treatment responders vs non-responders

    To characterise and compare the T cell receptor (TCR) repertoire in transplant recipients who were responsive and not responsive to the various corticosteroid dosing strategies in acute TCMR. 1. T cell receptor repertoire (Australia) 2. Urine chemokines (Canada) 3. HLA eplet analysis (Canada) 4. Biopsy transcriptomics (B-HOT panel, Canada)

    Time frame: Week 13 to week 48 post-randomization

  6. Life participation

    Life participation will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS®) Ability to Participate in Social Roles and Activities - Short Form 4a (SF4a). This instrument measures perceived ability to perform usual social roles and activities. Scores are reported as T-scores standardized to the general U.S. population (mean = 50, SD = 10). * Minimum score: 20 * Maximum score: 80 Higher scores indicate better ability to participate in social roles and activities (i.e., a more favorable outcome).

    Time frame: Randomisation, week 12 post-randomization, week 24 post-randomization and week 48 post-randomization

  7. Transplant fibrosis ultrasound analysis

    Correlation of ultrasound images collected at the time of kidney biopsy with histologic and clinical parameters (Canadian and Australian participating centers)

    Time frame: Week 13 to week 48 post-randomization

07

Study locations

2 of 30 sites recruiting
  • John Hunter Hospital
    Lambton, New South Wales 2305, Australia
    Not yet recruiting
    • Thida Myint, FRACP · Principal investigator
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
    Not yet recruiting
    • Kenneth Yong, FRACP, PhD · Principal investigator
  • The Sydney Children's Hospital Network
    Westmead, New South Wales 2145, Australia
    Not yet recruiting
    • Siah Kim, FRACP, PhD · Principal investigator
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Germaine Wong, FRACP, Phd · Principal investigator
  • Queensland Children's Hospital
    South Brisbane, Queensland 2014, Australia
    Recruiting
    • Anna Francis, PhD, FRACP · Principal investigator
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
    Not yet recruiting
    • Ryan Gately, MBBS, Mbiostat, MClinEpi · Principal investigator
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
    Not yet recruiting
    • Michael Collins, FRACP, PhD · Principal investigator
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
    Not yet recruiting
    • William Mulley, FRACP, PhD · Principal investigator
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
    Not yet recruiting
    • Suda Swaminathan, MBBS, FRACP, MCR · Principal investigator
  • Royal Perth Children's hospital
    Nedlands, Western Australia 6009, Australia
    Not yet recruiting
    • Nick Larkins, FRACP, PhD · Principal investigator
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
    Not yet recruiting
    • Wai Lim, FRACP, PHD · Principal investigator
  • Foothills Medical Centre
    Calgary, Alberta T2N 4Z6, Canada
    Not yet recruiting
    • Ngan Lam, MD, MSc · Principal investigator
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
    Not yet recruiting
    • Lorraine Hamiwka, MD · Principal investigator
  • Stollery Children's Hospital
    Edmonton, Alberta T6G 1C9, Canada
    Not yet recruiting
    • Michelle Ruhl, MD, FRCPC · Principal investigator
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
    Not yet recruiting
    • Emily Christie, MD, FRCPC · Principal investigator
  • BC Children's Hospital
    Vancouver, British Columbia T6G 1C9, Canada
    Not yet recruiting
    • Tom Blydt-Hansen, MD · Principal investigator
  • HSC Winnipeg Children's
    Winnipeg, Manitoba R3A 1R9, Canada
    Not yet recruiting
    • Aviva Goldberg, MD · Principal investigator
  • Health Sciences Center, University of Manitoba
    Winnipeg, Manitoba, Canada
    Not yet recruiting
    • Julie Ho, FRCPC · Principal investigator
  • QEII Health Sciences Centre, Nova Scotia Health Authority
    Halifax, Nova Scotia B3H 1V8, Canada
    Not yet recruiting
    • Amanda Vinson, MD · Principal investigator
  • London Health Science Centre
    London, Ontario N6A 5A5, Canada
    Not yet recruiting
    • Matthew Weir, MD, FRCPC · Principal investigator
  • St Mike's Hospital (Unity Health)
    Toronto, Ontario M5B 1W8, Canada
    Not yet recruiting
    • Darren Yuen, MD, PhD · Principal investigator
  • University of Toronto - Hospital for Sick Kids
    Toronto, Ontario M5G 1E8, Canada
    Not yet recruiting
    • Chia Wei Teoh, MB B.Ch., BAO, LRCSI, MRCPI · Principal investigator
  • Toronto General Hospital Research Institute (UHN)
    Toronto, Ontario M5G 2N2, Canada
    Not yet recruiting
    • Joseph Kim, MD, PhD · Principal investigator
  • Centre Hospitalier de l'université de Montréal (CHUM)
    Montreal, Quebec H2X 0A9, Canada
    Not yet recruiting
    • Daniel Fantus, MD, FRCPC · Principal investigator
  • Glen Site
    Montreal, Quebec H3J 0A9, Canada
    Not yet recruiting
    • Shaifali Sandal, MD · Principal investigator
  • CHU Ste-Justine
    Montreal, Quebec H3T 1C5, Canada
    Not yet recruiting
    • Véronique Phan, MD · Principal investigator
  • Montreal Children's Hospital
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
    • Beth Foster, MD, MSCE · Principal investigator
  • CHU de Quebec
    Québec, Quebec G1R 2J6, Canada
    Not yet recruiting
    • Sacha De Serres, MD, FRCPC · Principal investigator
  • St. Paul's Hospital
    Saskatoon, Saskatchewan S7M 0Z9, Canada
    Not yet recruiting
    • Rahul Manira, MD, FRCPC · Principal investigator
  • Auckland City Hospital
    Grafton, Auckland 1023, New Zealand
    Not yet recruiting
    • Helen Pilmore · Principal investigator
08

References and documents

Publications

  • Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012 May;12(5):1157-67. doi: 10.1111/j.1600-6143.2012.04013.x. Epub 2012 Mar 19. PubMed 22429309 ↗
  • Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, Goldberg A, Karpinski M, Shaw J, Rush DN, Nickerson PW. HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant. 2019 Jun;19(6):1708-1719. doi: 10.1111/ajt.15177. Epub 2018 Dec 15. PubMed 30414349 ↗
  • Wiebe C, Rush DN, Gibson IW, Pochinco D, Birk PE, Goldberg A, Blydt-Hansen T, Karpinski M, Shaw J, Ho J, Nickerson PW. Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection. Am J Transplant. 2020 Sep;20(9):2499-2508. doi: 10.1111/ajt.15860. Epub 2020 Apr 9. PubMed 32185878 ↗
  • Nickerson PW, Balshaw R, Wiebe C, Ho J, Gibson IW, Bridges ND, Rush DN, Heeger PS. A noninferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation. Am J Transplant. 2021 Apr;21(4):1503-1512. doi: 10.1111/ajt.16311. Epub 2020 Oct 6. PubMed 32956576 ↗
  • Rampersad C, Balshaw R, Gibson IW, Ho J, Shaw J, Karpinski M, Goldberg A, Birk P, Rush DN, Nickerson PW, Wiebe C. The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am J Transplant. 2022 Mar;22(3):761-771. doi: 10.1111/ajt.16883. Epub 2021 Nov 24. PubMed 34717048 ↗
  • Ho J, Okoli GN, Rabbani R, Lam OLT, Reddy VK, Askin N, Rampersad C, Trachtenberg A, Wiebe C, Nickerson P, Abou-Setta AM. Effectiveness of T cell-mediated rejection therapy: A systematic review and meta-analysis. Am J Transplant. 2022 Mar;22(3):772-785. doi: 10.1111/ajt.16907. Epub 2021 Dec 10. PubMed 34860468 ↗
  • Nankivell BJ, Shingde M, Keung KL, Fung CL, Borrows RJ, O'Connell PJ, Chapman JR. The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. Am J Transplant. 2018 Feb;18(2):364-376. doi: 10.1111/ajt.14609. Epub 2018 Jan 3. PubMed 29194971 ↗
  • Tong A, Budde K, Gill J, Josephson MA, Marson L, Pruett TL, Reese PP, Rosenbloom D, Rostaing L, Warrens AN, Wong G, Craig JC, Crowe S, Harris T, Hemmelgarn B, Manns B, Tugwell P, Van Biesen W, Wheeler DC, Winkelmayer WC, Evangelidis N, Sautenet B, Howell M, Chapman JR. Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. Transplant Direct. 2016 May 19;2(6):e79. doi: 10.1097/TXD.0000000000000593. eCollection 2016 Jun. PubMed 27500269 ↗
  • Sautenet B, Tong A, Chapman JR, Warrens AN, Rosenbloom D, Wong G, Gill J, Budde K, Rostaing L, Marson L, Josephson MA, Reese PP, Pruett TL, Evangelidis N, Craig JC. Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review. Transplantation. 2018 Dec;102(12):2065-2071. doi: 10.1097/TP.0000000000002278. PubMed 29781954 ↗
  • Sautenet B, Tong A, Manera KE, Chapman JR, Warrens AN, Rosenbloom D, Wong G, Gill J, Budde K, Rostaing L, Marson L, Josephson MA, Reese PP, Pruett TL, Hanson CS, O'Donoghue D, Tam-Tham H, Halimi JM, Shen JI, Kanellis J, Scandling JD, Howard K, Howell M, Cross N, Evangelidis N, Masson P, Oberbauer R, Fung S, Jesudason S, Knight S, Mandayam S, McDonald SP, Chadban S, Rajan T, Craig JC. Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals. Transplantation. 2017 Aug;101(8):1875-1886. doi: 10.1097/TP.0000000000001776. PubMed 28738403 ↗
  • Tong A, Gill J, Budde K, Marson L, Reese PP, Rosenbloom D, Rostaing L, Wong G, Josephson MA, Pruett TL, Warrens AN, Craig JC, Sautenet B, Evangelidis N, Ralph AF, Hanson CS, Shen JI, Howard K, Meyer K, Perrone RD, Weiner DE, Fung S, Ma MKM, Rose C, Ryan J, Chen LX, Howell M, Larkins N, Kim S, Thangaraju S, Ju A, Chapman JR; SONG-Tx Investigators. Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops. Transplantation. 2017 Aug;101(8):1887-1896. doi: 10.1097/TP.0000000000001774. PubMed 28737661 ↗
  • Tong A, Sautenet B, Poggio ED, Lentine KL, Oberbauer R, Mannon R, Murphy B, Padilla B, Chow KM, Marson L, Chadban S, Craig JC, Ju A, Manera KE, Hanson CS, Josephson MA, Knoll G; SONG-Tx Graft Health Workshop Investigators. Establishing a Core Outcome Measure for Graft Health: A Standardized Outcomes in Nephrology-Kidney Transplantation (SONG-Tx) Consensus Workshop Report. Transplantation. 2018 Aug;102(8):1358-1366. doi: 10.1097/TP.0000000000002125. PubMed 29470347 ↗
  • Ju A, Josephson MA, Butt Z, Jowsey-Gregoire S, Tan J, Taylor Q, Fowler K, Dobbels F, Caskey F, Jha V, Locke J, Knoll G, Ahn C, Hanson CS, Sautenet B, Manera K, Craig JC, Howell M, Rutherford C, Tong A, Harden P, Hawley C, Holdaas H, Israni A, Jesse M, Kane B, Kanellis J, Kiberd B, Kim J, Larsen C, Leichtman A, Lentine K, Malone A, Mannon R, Oberbauer R, Patzer R, Peipert JD, Phan HA, Poggio E, Reed R, Scandling J, Tang I, Watson C, Contrares D, Contreras P, Cross D, Juodvalkis E, Koide D, Koide J, Kozarewicz A, Kozarewicz L, Kozarewicz R, Koritala A, Lisiecki E, Lipuma C, Lyman M, Mueller R, Mueller G, Noble L, Nolan N, Nolan S, Thomas J, Urbancyzk L, Zerante J, Zerante S; SONG-Tx Life Participation Workshop Investigators; Health professionals (*includes 2 patients from the SONG-Tx Graft Health Expert Working Group); Patients and family members. Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report. Transplantation. 2019 Jun;103(6):1199-1205. doi: 10.1097/TP.0000000000002476. PubMed 30300284 ↗
  • Ju A, Chow BY, Ralph AF, Howell M, Josephson MA, Ahn C, Butt Z, Dobbels F, Fowler K, Jowsey-Gregoire S, Jha V, Locke JE, Tan JC, Taylor Q, Rutherford C, Craig JC, Tong A. Patient-reported outcome measures for life participation in kidney transplantation: A systematic review. Am J Transplant. 2019 Aug;19(8):2306-2317. doi: 10.1111/ajt.15267. Epub 2019 Feb 28. PubMed 30664327 ↗

Individual participant data

Plan to share: Yes — The data collected for the study, including individual patient data and a data dictionary that defines each field in the data set, will be made available as deidentified participant data to researchers who propose to use the data for individual patient data meta-analysis. Data will be shared following approval of the proposal by the corresponding author and a signed data access agreement, beginning 2 years following main publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Study protocol, SAP, ICF will be provided 3 months after registration. The Clinical study report and code will be provided after completion of the trial.

Access criteria: All IPD data arising from the trial will be shared 2 years after publication of the main results.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2024
First posted
Jun 25, 2024
StartActual
Mar 13, 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06474273
Lead sponsor
University of Sydney
Responsible party
Sponsor
First posted
Jun 25, 2024
Start date
Mar 13, 2026
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Aug 31, 2026

Study contacts

NHMRC Clinical Trials Centre THE UNIVERSITY OF SYDNEY
Contact
tackle-it.study@sydney.edu.au
+61 2 9562 5000
Germaine Wong, PhD, FRACP
principal investigator · University of Sydney
Julie Ho, FRCPC
principal investigator · University of Manitoba

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methylprednisolone · Prednisone

Start the discussion